GANX
USDGain Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.810
High
$1.810
Low
$1.660
Volume
0.57M
Company Fundamentals
Market Cap
59.7M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.68M
Exchange
NGM
Currency
USD
52-Week Range
Related News
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.